Literature DB >> 28186762

Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Vivek Kumar1, Amy E Moritz2, Thomas M Keck1, Alessandro Bonifazi1, Michael P Ellenberger1, Christopher D Sibley1, R Benjamin Free2, Lei Shi3, J Robert Lane4, David R Sibley2, Amy Hauck Newman1.   

Abstract

The development of bitopic ligands directed toward D2-like receptors has proven to be of particular interest to improve the selectivity and/or affinity of these ligands and as an approach to modulate and bias their efficacies. The structural similarities between dopamine D3 receptor (D3R)-selective molecules that display bitopic or allosteric pharmacology and those that are simply competitive antagonists are subtle and intriguing. Herein we synthesized a series of molecules in which the primary and secondary pharmacophores were derived from the D3R-selective antagonists SB269,652 (1) and SB277011A (2) whose structural similarity and pharmacological disparity provided the perfect templates for SAR investigation. Incorporating a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, 18a and 25a, which further delineates SAR associated with allosterism at D3R and provides leads toward novel drug development.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28186762      PMCID: PMC5325712          DOI: 10.1021/acs.jmedchem.6b01688

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  44 in total

Review 1.  Allosteric modulation of G protein-coupled receptors.

Authors:  Lauren T May; Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

2.  N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.

Authors:  Ashwini K Banala; Benjamin A Levy; Sameer S Khatri; Cheryse A Furman; Rebecca A Roof; Yogesh Mishra; Suzy A Griffin; David R Sibley; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2011-05-02       Impact factor: 7.446

3.  Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons.

Authors:  E V Gurevich; J N Joyce
Journal:  Neuropsychopharmacology       Date:  1999-01       Impact factor: 7.853

Review 4.  Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.

Authors:  Fabrizio Micheli
Journal:  ChemMedChem       Date:  2011-03-18       Impact factor: 3.466

5.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

Review 6.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

7.  The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.

Authors:  Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

8.  Development of versatile cis- and trans-dicarbon-substituted chiral cyclopropane units: synthesis of (1S,2R)- and (1R,2R)-2-aminomethyl-1-(1H-imidazol-4-yl)cyclopropanes and their enantiomers as conformationally restricted analogues of histamine.

Authors:  Yuji Kazuta; Akira Matsuda; Satoshi Shuto
Journal:  J Org Chem       Date:  2002-03-08       Impact factor: 4.354

9.  The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.

Authors:  Tanaji T Talele
Journal:  J Med Chem       Date:  2016-06-30       Impact factor: 7.446

Review 10.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.

Authors:  Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

View more
  15 in total

Review 1.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

2.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

3.  Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.

Authors:  Amy E Moritz; R Benjamin Free; Warren S Weiner; Emmanuel O Akano; Disha Gandhi; Ara Abramyan; Thomas M Keck; Marc Ferrer; Xin Hu; Noel Southall; Joseph Steiner; Jeffrey Aubé; Lei Shi; Kevin J Frankowski; David R Sibley
Journal:  J Med Chem       Date:  2020-05-12       Impact factor: 7.446

4.  The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists.

Authors:  Francisco O Battiti; Sophie L Cemaj; Adrian M Guerrero; Anver Basha Shaik; Jenny Lam; Rana Rais; Barbara S Slusher; Jeffery R Deschamps; Greg H Imler; Amy Hauck Newman; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-07-01       Impact factor: 7.446

5.  Strategies for targeting cell surface proteins using multivalent conjugates and chemical biology.

Authors:  Shivani Sachdev; Chino C Cabalteja; Ross W Cheloha
Journal:  Methods Cell Biol       Date:  2021-07-12       Impact factor: 1.829

6.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

Review 7.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

8.  Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management.

Authors:  Alessandro Bonifazi; Francisco O Battiti; Julie Sanchez; Saheem A Zaidi; Eric Bow; Mariia Makarova; Jianjing Cao; Anver Basha Shaik; Agnieszka Sulima; Kenner C Rice; Vsevolod Katritch; Meritxell Canals; J Robert Lane; Amy Hauck Newman
Journal:  J Med Chem       Date:  2021-05-20       Impact factor: 8.039

9.  Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer.

Authors:  Daniel Pulido; Verònica Casadó-Anguera; Laura Pérez-Benito; Estefanía Moreno; Arnau Cordomí; Laura López; Antoni Cortés; Sergi Ferré; Leonardo Pardo; Vicent Casadó; Miriam Royo
Journal:  J Med Chem       Date:  2018-10-11       Impact factor: 8.039

10.  The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.

Authors:  Ravi Kumar Verma; Ara M Abramyan; Mayako Michino; R Benjamin Free; David R Sibley; Jonathan A Javitch; J Robert Lane; Lei Shi
Journal:  PLoS Comput Biol       Date:  2018-01-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.